[{"ID":"35384_75-2021_NCT00865371","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a healthy, normal adult man who volunteers to participate, is 18-45 years of age, has a BMI \u226430, is considered reliable and capable of understanding his responsibility and role in the study, and has provided written informed consent. Therefore, the answer is yes, the patient meets the inclusion criteria.\n\n#2: Does the patient meet the exclusion criteria?\n\nThe patient does not have a history of allergy or hypersensitivity to bupropion, milk or eggs, does not smoke more than 25 cigarettes\/day, and does not have a history of seizure, cranial trauma, or other predisposition to seizure. The patient also does not have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his safety, and does not have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, renal or other diseases, conditions or surgeries that would interfere with the conduct or interpretation of the study or jeopardize his safety. The patient also does not have serious psychological illness, and does not have significant history (within the past six months) or clinical evidence of alcohol or drug abuse. The patient also does not have a positive urine drug screen or saliva alcohol screen, or a positive HIV-l, or hepatitis B or C screen. Therefore, the answer is no, the patient does not meet the exclusion criteria.\n\nBased on the above, the patient is eligible for the clinical trial. Therefore, the answer is A: eligible.","PROBA":0.9911254128},{"ID":"28014_40-2022_NCT04053699","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a 23-year-old female with a history of heavy menstrual cycles and a recent episode of prolonged oral bleeding after tooth extraction, which responded to desmopressin (DDAVP) administration. She has no other medical problems and takes no medications. Her mother and grandmother have also had excessive bleeding during menstrual periods.\n\nBased on the inclusion criteria, the patient meets criteria #1, as she has VWD type 1 (baseline von Willebrand factor activity [VWF:RCo], <30 IU\/dL) and is currently receiving frequent on-demand treatment with a VWF-containing product to control bleeding.\n\n#2: Does the patient meet the exclusion criteria?\n\nThe patient does not meet exclusion criterion #1, as she is not currently on prophylaxis for VWD and has not received treatment once a month for menstrual bleeding. She also does not have a history or current suspicion of VWF or FVIII inhibitors, medical history of a thromboembolic event within 6 months before enrolment, severe liver or kidney diseases, or other coagulation disorders or bleeding disorders due to anatomical reasons.\n\nThe patient does meet exclusion criterion #2, as she is of child-bearing potential and is not using hormonal contraception. However, this is not a disqualifying criterion, as the study allows for patients who are using hormonal contraception and will remain unchanged for the duration of their study participation.\n\n#3: Does the patient have any other conditions that would preclude her from participating in the study?\n\nThe patient has a history of heavy menstrual cycles and a recent episode of prolonged oral bleeding after tooth extraction, which responded to desmopressin (DDAVP) administration. However, these conditions do not preclude her from participating in the study, as they are related to her VWD and are being treated with on-demand therapy.\n\nBased on the above, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9931121639},{"ID":"30398_65-2021_NCT00125437","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have nonischemic cardiomyopathy?\n\nYes, the patient has nonischemic cardiomyopathy.\n\n#2: Does the patient have a left ventricular ejection fraction (LVEF) of less than 35%?\n\nYes, the patient has a LVEF of less than 35%.\n\n#3: Is the patient's renal function preserved?\n\nYes, the patient's renal function is preserved (Cr \u22642.5 mg\/dL in males; Cr \u22642.0mg\/dL in females).\n\n#4: Does the patient have any of the exclusion criteria?\n\nNo, the patient does not have any of the exclusion criteria (hyperkalemia, left ventricular systolic dysfunction with pericardial diseases, congenital heart diseases, pulmonary heart diseases, heart valvular diseases, acute coronary syndrome, or short life expectancy).\n\nTherefore, based on the criteria for the clinical trial, the patient is eligible for the study.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9985818804},{"ID":"25078_53-2021_NCT01402115","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have reduced bone density but no evidence of osteoporosis or osteopenia?\n\n#2: Is the patient a perimenopausal woman aged 40-70?\n\n#3: Does the patient have any exclusion criteria?\n\nPlease answer each question with either \"yes\" or \"no\" before moving on to the next question.","PROBA":0.9717698522},{"ID":"5309_12-2021_NCT01621971","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have chronic mitral regurgitation?\n\nYes, the patient has chronic mitral regurgitation.\n\n#2. Does the patient have an estimated pulmonary hypertension (systolic PAP > 50 mmHg)?\n\nYes, the patient has an estimated pulmonary hypertension (systolic PAP > 50 mmHg) based on the preoperative transthoracic echocardiography.\n\n#3. Is the patient undergoing mitral valve surgery?\n\nYes, the patient is undergoing mitral valve surgery.\n\n#4. Has the patient agreed to participate in the study and signed written informed consent?\n\nNo, the patient has not agreed to participate in the study and signed written informed consent.\n\nBased on the above, the patient is not eligible for the clinical trial because they do not meet the inclusion criteria of having agreed to participate in the study and signed written informed consent.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9968845507},{"ID":"18652_27-2022_NCT00005657","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient have HCV infection?\n\nYes, the patient has HCV infection, as indicated by positive anti-HCV and HCV viremia.\n\n#2: Does the patient have rapid progressive severe liver disease and\/or hepatocellular carcinoma?\n\nNo, the patient does not have rapid progressive severe liver disease and\/or hepatocellular carcinoma, as indicated by the absence of these conditions in the patient's history.\n\n#3: Has the patient undergone or is the patient undergoing treatment?\n\nNo, the patient has not undergone any treatment for HCV infection.\n\n#4: Is the patient a healthy volunteer?\n\nNo, the patient is not a healthy volunteer, as they have HCV infection.\n\n#5: Does the patient have other forms of liver disease?\n\nNo, the patient does not have other forms of liver disease, as indicated by the absence of other liver diseases in the patient's history.\n\nBased on the above criteria, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible.","PROBA":0.99397382},{"ID":"35639_75-2021_NCT03301272","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a 55-year-old man with Parkinson's disease, which meets criterion #1.\n\n#2: Does the patient have a rest tremor of at least 3 cm amplitude?\n\nYes, the patient has a rest tremor of at least 3 cm amplitude, which meets criterion #3.\n\n#3: Is the patient's rest tremor historically refractory to at least 2 categories of medications?\n\nYes, the patient's rest tremor is historically refractory to at least 2 categories of medications, which meets criterion #5.\n\n#4: Is the patient able to make no changes to their anti-parkinsonian medications for 150 days?\n\nYes, the patient is able to make no changes to their anti-parkinsonian medications for 150 days, which meets criterion #6.\n\n#5: Does the patient have any exclusion criteria?\n\nNo, the patient does not have any exclusion criteria, such as a history of botulinum toxin injections, allergy to carbidopa or levodopa, or pregnancy.\n\nTherefore, based on the provided information, the patient would likely be considered eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9913602898},{"ID":"35828_75-2021_NCT04821830","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Is the patient's disease mild to moderate (Hoehn & Yahr Stages I-II)?\n\nYes, the patient's disease is classified as mild to moderate (Hoehn & Yahr Stages I-II).\n\n#3: Is the patient about to start treatment with a L-Dopa preparation (Sinemet)?\n\nNo, the patient is not currently taking any medication for their Parkinson's disease.\n\n#4: Does the patient have any exclusion criteria?\n\nNo, the patient does not have any of the exclusion criteria listed (depression, use of dopamine agonists or stimulants, evidence of a stroke or mass lesion on prior structural brain imaging, or cognitive impairment that might impair their capacity to provide informed consent).\n\nTherefore, based on the criteria for the clinical trial, the patient would be considered eligible for the study.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9893694506},{"ID":"35538_75-2021_NCT02370134","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Does the patient have a predominantly rest tremor that is intractable to medical treatment?\n\nYes, the patient has a predominantly rest tremor that is not responding well to medical treatment.\n\n#3: Is the patient at least 18 years old?\n\nYes, the patient is an adult.\n\n#4: Does the patient have any exclusion criteria?\n\nNo, the patient does not have any exclusion criteria.\n\nTherefore, based on the inclusion and exclusion criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9901831348},{"ID":"35697_75-2021_NCT03808675","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Is the patient's disease ranked as mild, Hoehn-Yahr Stage I?\n\nYes, the patient's disease is ranked as mild, Hoehn-Yahr Stage I.\n\n#3: Is the patient on a stable regimen of central nervous system acting medications for 30 days prior to the baseline visit?\n\nNo, the patient is not on any central nervous system acting medications.\n\n#4: Does the patient have any confounding acute or unstable medical, psychiatric, orthopedic condition?\n\nNo, the patient does not have any confounding acute or unstable medical, psychiatric, orthopedic condition.\n\n#5: Is the patient currently active in driving?\n\nYes, the patient is currently active in driving.\n\n#6: Does the patient have a valid driver's license?\n\nYes, the patient has a valid driver's license.\n\n#7: Is the patient willing and able to give informed consent?\n\nYes, the patient is willing and able to give informed consent.\n\nBased on the criteria, the patient is eligible for the clinical trial.\n\nTherefore, the answer is:\n\nA: Eligible","PROBA":0.9864093839},{"ID":"35511_75-2021_NCT02037451","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have Parkinson's disease?\n\nYes, the patient has been clinically diagnosed with Parkinson's disease.\n\n#2. Are there any other neurological diseases?\n\nNo, there are no other neurological diseases.\n\n#3. Does the patient have dementia?\n\nNo, there is no evidence of dementia.\n\n#4. Does the patient have any mental illness?\n\nNo, there is no evidence of any mental illness.\n\n#5. Has the patient had any history of seizures?\n\nNo, there is no history of seizures.\n\n#6. Has the patient had any brain trauma?\n\nNo, there is no history of brain trauma.\n\n#7. Does the patient have a pacemaker or other electrical stimulator?\n\nNo, there is no evidence of a pacemaker or other electrical stimulator.\n\n#8. Is the patient pregnant?\n\nNo, the patient is not pregnant.\n\nBased on the criteria, the patient is eligible for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9929150659},{"ID":"14149_30-2021_NCT03097237","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have a BMI of 27-35 kg\/m2?\n\nYes, the patient has a BMI of 31, which is within the inclusion criteria range of 27-35 kg\/m2.\n\n#2. Does the patient have Hb\u2265120g\/l?\n\nYes, the patient's Hb is 130 g\/l, which is within the inclusion criteria range of Hb\u2265120g\/l.\n\n#3. Does the patient have serum TSH \u22644.00 mIU\/L?\n\nNo, the patient's serum TSH is 13 mU\/L, which is outside the inclusion criteria range of serum TSH \u22644.00 mIU\/L.\n\n#4. Does the patient have plasma low density lipoprotein cholesterol <5.3 mmol\/L?\n\nNo, the patient's plasma low density lipoprotein cholesterol is not specified, but it is outside the inclusion criteria range of <5.3 mmol\/L.\n\n#5. Does the patient have plasma triglycerides \u22641.8 mmol\/L?\n\nNo, the patient's plasma triglycerides are not specified, but it is outside the inclusion criteria range of \u22641.8 mmol\/L.\n\n#6. Is the patient willing and able to provide informed consent?\n\nYes, the patient is willing and able to provide informed consent.\n\n#7. Is the patient able to complete satisfactorily the 3-day weighted food record at screening visit 2?\n\nNo, the patient is not able to complete satisfactorily the 3-day weighted food record at screening visit 2, as it is not specified in the patient's note.\n\n#8. Is the patient willing and able to lose 0.5 kg or more during the run-in period for men and women not having menstruation during the run-in period?\n\nNo, the patient is not willing and able to lose 0.5 kg or more during the run-in period, as it is not specified in the patient's note.\n\n#9. Is the patient using nicotine products on a daily basis or e-cigarettes?\n\nNo, the patient is not using nicotine products on a daily basis or e-cigarettes.\n\n#10. Has the patient followed any weight reduction program or had followed one during the last 6 months prior to visit 1?\n\nNo, the patient has not followed any weight reduction program or had followed one during the last 6 months prior to visit 1.\n\n#11. Does the patient have a history of stomach or gastrointestinal conditions?\n\nNo, the patient does not have a history of stomach or gastrointestinal conditions.\n\n#12. Does the patient have a history of heart failure or heart attack within 1 year prior to screening?\n\nNo, the patient does not have a history of heart failure or heart attack within 1 year prior to screening.\n\n#13. Does the patient have type I diabetes?\n\nNo, the patient does not have type I diabetes.\n\n#14. Is the patient receiving pharmacological treatment for type II diabetes?\n\nNo, the patient is not receiving pharmacological treatment for type II diabetes.\n\n#15. Does the patient have previous gastrointestinal surgery?\n\nNo, the patient does not have previous gastrointestinal surgery.\n\n#16. Does the patient have thyroid disorder?\n\nNo, the patient does not have thyroid disorder.\n\n#17. Does the patient have a history of drug or alcohol abuse?\n\nNo, the patient does not have a history of drug or alcohol abuse.\n\n#18. Does the patient have stroke or transient ischemic attack (TIA) within 1 year prior to screening?\n\nNo, the patient does not have stroke or transient ischemic attack (TIA) within 1 year prior to screening.\n\n#19. Is the patient pregnant or lactating or wish to become pregnant during the period of the study?\n\nNo, the patient is not pregnant or lactating or wish to become pregnant during the period of the study.\n\n#20. Does the patient have food allergies or","PROBA":0.9954261392},{"ID":"6765_15-2021_NCT01897623","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have coronary artery disease?\n\nYes, the patient has a history of coronary artery disease (CAD) with angioplasty in [**State 108**] one year ago.\n\n#2. Is the patient male?\n\nYes, the patient is male.\n\n#3. Does the patient have any of the exclusion criteria?\n\nNo, the patient does not have any of the exclusion criteria (female gender or already diagnosed or treated abdominal aortic aneurysm).\n\nTherefore, based on the inclusion and exclusion criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9950650789},{"ID":"35774_75-2021_NCT04308135","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease, so this criterion is met.\n\n#2: Does the patient have evidence of cerebrovascular disease by brain imaging?\n\nNo, there is no mention of brain imaging in the patient's note, so this criterion is not met.\n\n#3: Is there an established relationship between the two disorders?\n\nNo, there is no mention of an established relationship between the two disorders in the patient's note, so this criterion is not met.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is \"excluded\" from the clinical trial.","PROBA":0.9836138716},{"ID":"23470_33-2022_NCT03059043","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient have a stable refraction?\n\nYes, the patient has a stable refraction for at least 1 year, which meets the inclusion criterion.\n\n#2: Does the patient have a best-corrected visual acuity (BCVA) of 20\/40 or better?\n\nYes, the patient has a BCVA of 20\/40 or better, which meets the inclusion criterion.\n\n#3: Does the patient have a clear central cornea?\n\nYes, the patient has a clear central cornea, which meets the inclusion criterion.\n\n#4: Does the patient have a myopic refractive error within the range of -0.5D to -18.0D?\n\nYes, the patient has a myopic refractive error within the range of -0.5D to -18.0D, which meets the inclusion criterion.\n\n#5: Does the patient have a normal anterior chamber depth at least 2.8 mm to endothelium?\n\nNo, the patient does not have a normal anterior chamber depth, as the anterior chamber depth is not specified in the patient note. Therefore, this criterion is not met.\n\n#6: Does the patient have an endothelial cell density (ECD) of more than 2000 cell\/mm2?\n\nNo, the patient does not have an ECD of more than 2000 cell\/mm2, as the ECD is not specified in the patient note. Therefore, this criterion is not met.\n\n#7: Does the patient have a pupil diameter smaller than 7.0 mm under mesopic condition?\n\nYes, the patient has a pupil diameter smaller than 7.0 mm under mesopic condition, which meets the inclusion criterion.\n\n#8: Is the patient discontinued from wearing hard contact lens for at least 3 weeks or soft contact lens for at least 1 week?\n\nNo, the patient is not discontinued from wearing contact lenses, as the patient note does not mention any information about contact lens wear. Therefore, this criterion is not met.\n\nBased on the above assessment, the patient is not eligible for the clinical trial because the patient does not have a normal anterior chamber depth and does not meet the ECD criterion.","PROBA":0.9928697634},{"ID":"13938_30-2021_NCT00271427","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have AIT?\n\nYes, the patient has been diagnosed with Hashimoto's thyroiditis, which is a type of AIT.\n\n#2. Is the patient not using any medication other than LT4 to keep TSH in the lower half of normal range?\n\nNo, the patient is currently taking Levothyroxine (LT4) to keep her TSH levels in the normal range. Therefore, she does not meet the inclusion criterion.\n\n#3. Does the patient have any known pathology that may affect GIS absorption?\n\nNo, there is no information about any known pathology that may affect GIS absorption.\n\nBased on the information provided, the patient is not eligible for the clinical trial because she is currently taking medication (Levothyroxine) to keep her TSH levels in the normal range, which is an exclusion criterion.","PROBA":0.979368394},{"ID":"5545_12-2021_NCT04527367","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have valvular heart disease?\n\nYes, the patient has valvular heart disease (VHD).\n\n#2. Is the patient's VHD in moderate to severe stages?\n\nYes, the patient's VHD is in moderate to severe stages.\n\n#3. Is the patient at least 18 years old?\n\nNo, the patient is 34 years old, which is less than 18 years old.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9914170895},{"ID":"27645_40-2022_NCT01526915","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a major (male or female) with a documented indication for a maximum extraction of 3 teeth, and they have been treated with nitrogenous or non-nitrogenous bisphosphonates (BP) by intravenous injection or oral administration. Therefore, the patient meets the inclusion criteria.\n\n#2: Does the patient meet the exclusion criteria?\n\nThe patient does not have a maxillary or mandibular osteonecrosis at Day 0 (JO), and they do not have a previous history of maxillo-cervico-facial radiotherapy. They also have estimated survival expectancy of more than one year and have social security cover. Therefore, the patient does not meet any of the exclusion criteria.\n\nBased on the above, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9958852092},{"ID":"27964_40-2022_NCT03751800","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a woman in childbearing age (23 years old) and is not pregnant. She has been diagnosed with heavy menstrual bleeding and is willing to receive chronic hormonal treatment for HMB. Therefore, the patient meets the inclusion criteria.\n\n#2: Does the patient meet any of the exclusion criteria?\n\nThe patient does not have amenorrhea or menopause, and she is not receiving hormone replacement therapy. She is not taking any concomitant medication that may lead to changes in the bleeding pattern (e.g. antiplatelet and\/or anticoagulants). Therefore, the patient does not meet any of the exclusion criteria.\n\nBased on the information provided, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.993558708},{"ID":"33481_71-2021_NCT00909766","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is obese (BMI = 41.54), which meets the inclusion criterion of a BMI of 30 to 40 kg\/m\u00b2, inclusive.\n\n#2: Does the patient meet the exclusion criteria?\n\nThe patient does not have any of the exclusion criteria listed, such as evidence of organ dysfunction, abnormal blood work results, high blood pressure, or a history of suicide attempt.\n\nTherefore, based on the information provided, the patient would likely be considered eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9924897036},{"ID":"6892_15-2021_NCT02972671","TOPIC_YEAR":2021,"RESPONSE":"#1. Is the patient male or female?\n\n#2. Is the patient \u226520 years old?\n\n#3. Is the patient eligible for percutaneous coronary intervention (PCI)?\n\n#4. Does the patient have a reference vessel diameter ranging from 2.5 mm to 3.75 mm?\n\n#5. Will the patient be able to return for outpatient clinic at 1, 6, and 12 months follow-up?\n\nPlease select one of the options below based on the patient's information:\n\nA. Eligible\nB. Excluded\nC. Irrelevant\n\nPlease provide your answer.","PROBA":0.9885181271},{"ID":"6630_15-2021_NCT00630513","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have a community-acquired intra-abdominal infection (IAI)?\n\nYes, the patient has a community-acquired IAI, specifically acute diverticulitis with perforation and abscess.\n\n#2. Does the patient require surgical intervention within 24 hours of diagnosis?\n\nYes, the patient requires surgical intervention within 24 hours of diagnosis for the management of the perforated diverticulitis.\n\n#3. Does the patient have any of the exclusion criteria?\n\nNo, the patient does not have any of the exclusion criteria, such as a history of allergy or severe reaction to the study antibiotics, rapidly progressive or terminal illness, severe hepatic or renal disease, or concomitant infection that would interfere with evaluation of response to the study antibiotics.\n\nTherefore, based on the inclusion and exclusion criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9876676743},{"ID":"27599_40-2022_NCT01190150","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient have a history of at least one year of cyclic heavy menstrual bleeding?\n\nYes, the patient has a history of heavy menstrual bleeding for more than a year, which meets the inclusion criterion.\n\n#2: Is the patient ages 12-16 years old?\n\nYes, the patient is within the age range of 12-16 years old, which meets the inclusion criterion.\n\n#3: Does the patient have regularly occurring menstrual periods \u226410 days in duration, with 21-45 days from the start of one period to the start of the next menstrual period?\n\nYes, the patient has regularly occurring menstrual periods that are \u226410 days in duration, with a consistent interval of 21-45 days between periods, which meets the inclusion criterion.\n\n#4: Does the patient have a diagnosis of heavy menstrual bleeding based on the medical judgment of the Principal Investigator?\n\nYes, the patient has a diagnosis of heavy menstrual bleeding based on the medical judgment of the Principal Investigator, which meets the inclusion criterion.\n\n#5: Is the patient either sexually inactive (abstinent) or using one of the following acceptable birth control methods and agree to continue its use throughout the study?\n\nYes, the patient is either sexually inactive (abstinent) or using one of the acceptable birth control methods, which meets the inclusion criterion.\n\n#6: Does the patient have negative pregnancy test results?\n\nYes, the patient has negative pregnancy test results, which meets the inclusion criterion.\n\n#7: Has the patient legally authorized representative (e.g., parent, guardian) voluntarily signed a parental permission\/informed consent form (ICF), and the subject must sign an assent, before the conduct of any study procedure?\n\nNot applicable, as the patient is under the age of consent and requires a legal representative to sign the informed consent form.\n\nBased on the above assessment, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible.","PROBA":0.9917387162},{"ID":"14016_30-2021_NCT01420419","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have nipple pain with any sign of nipple trauma?\n\nYes, the patient does have nipple pain with signs of trauma (blistering, crusting, redness, bleeding, swelling, cracking, discoloration, or peeling). Therefore, the patient meets the inclusion criterion #1.\n\n#2: Is the infant delivered at, or greater than 37 weeks gestation?\n\nYes, the patient's infant was delivered at, or greater than 37 weeks gestation. Therefore, the patient meets the inclusion criterion #2.\n\n#3: Is the patient a singleton birth?\n\nYes, the patient had a singleton birth. Therefore, the patient meets the inclusion criterion #3.\n\n#4: Does the patient speak and understand English?\n\nYes, the patient speaks and understands English. Therefore, the patient meets the inclusion criterion #4.\n\n#5: Does the patient have access to a telephone?\n\nYes, the patient has access to a telephone. Therefore, the patient meets the inclusion criterion #5.\n\n#6: Does the patient have any exclusion criteria?\n\nNo, the patient does not have any exclusion criteria.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9980348496},{"ID":"35823_75-2021_NCT04796246","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\n#2: Is the patient's disease classified as mild (Hoehn-Yahr Stage I)?\n\n#3: Is the patient over 18 years old?\n\n#4: Does the patient reside in the city of Porto Alegre\/RS?\n\n#5: Has the patient signed an informed consent form?\n\nPlease answer these questions with a \"yes\" or \"no\" to determine if the patient is eligible for the clinical trial.","PROBA":0.9848954641},{"ID":"27622_40-2022_NCT01384331","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a healthy woman aged 18-45 using the subdermal progestogen-only contraceptive implant and experiencing frequent or prolonged vaginal bleeding. Yes, the patient meets the inclusion criteria.\n\n#2: Does the patient meet any of the exclusion criteria?\n\nThe patient does not have any of the exclusion criteria (heart attack or stroke, blood clot in a vein, high blood pressure, severe liver or kidney disease, migraine with aura, breast cancer or any genital cancer, severe chronic liver or kidney disease, known sensitivity to ethinyl oestradiol or progestogens, taking phenytoin, carbamazepine or phenobarbitol, pregnant, lactating, or unwilling to keep a daily menstrual diary or otherwise unwilling to follow the study criteria). No, the patient does not meet any of the exclusion criteria.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.\n\nSo, the answer is: A: eligible.","PROBA":0.9935433312},{"ID":"5561_12-2021_NCT04766216","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\nPlease select one of the following options:\n\nA: Eligible\nB: Excluded\nC: Irrelevant\n\nPlease provide your answer.","PROBA":0.9848480739},{"ID":"30724_65-2021_NCT02230631","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have T1DM or T2DM treated with insulin for more than 12 months?\n\nYes, the patient has T1DM treated with insulin for more than 12 months.\n\n#2: Is the patient at least 18 years old?\n\nYes, the patient is 25 years old, which is greater than 18 years old.\n\n#3: Does the patient have any exclusion criteria?\n\nNo, the patient does not have any exclusion criteria.\n\nTherefore, based on the inclusion and exclusion criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.988316613},{"ID":"5452_12-2021_NCT03390634","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have gastro-oesophageal symptoms in accordance with Montreal criteria?\n\nYes, the patient has gastro-oesophageal symptoms such as heartburn and an unpleasant taste in the back of the mouth, which are in accordance with Montreal criteria.\n\n#2: Was the oesophageal physiology testing performed at Guy's and St Thomas' NHS Foundation Trust?\n\nNo, the patient had the physiology testing at another center.\n\n#3: Is the patient at least 6 months post-ARS and follow-up at GSTT?\n\nNo, the patient had the surgery less than 6 months ago.\n\nBased on the criteria, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9883980886},{"ID":"35820_75-2021_NCT04781842","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2. Is the patient able to walk without physical assistance?\n\nNo, the patient has difficulty walking and needs guidance to step in.\n\nBased on the information provided, the patient is not eligible for the clinical trial because they do not meet the exclusion criteria of being unable to walk without physical assistance. Therefore, the answer is B: Excluded.","PROBA":0.9876665069},{"ID":"14087_30-2021_NCT02319538","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have typical symptoms believed to be related to Hashimoto's disease?\n\nYes, the patient has symptoms of fatigue, weight gain, and abnormal spotting between menses, which are typical symptoms of Hashimoto's disease.\n\n#2: Is the patient's anti-TPO level >1000?\n\nYes, the patient's anti-TPO level is extremely high (120 IU\/ml).\n\n#3: Is the patient hypothyroidism with a need for thyroxin supplementation?\n\nYes, the patient has hypothyroidism and is currently taking Levothyroxine.\n\n#4: Has the patient provided written informed consent?\n\nNot specified in the patient note, but it is assumed that the patient has provided informed consent since they are undergoing treatment.\n\nBased on the criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9880164452},{"ID":"6958_15-2021_NCT03527706","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have diverticular disease?\n\nYes, the patient has diverticular disease based on the CT abdomen without contrast showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass, which is consistent with pancreatic adenocarcinoma at the head of pancreas.\n\n#2: Is the patient scheduled for elective sigmoidectomy?\n\nNo, the patient is not scheduled for elective sigmoidectomy as the CT scan showed a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass, which is consistent with pancreatic adenocarcinoma at the head of pancreas.\n\n#3: Does the patient have any of the exclusion criteria?\n\nYes, the patient has one of the exclusion criteria, which is advanced malignancy with systemic metastases.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.9901732738},{"ID":"35733_75-2021_NCT04054960","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have Idiopathic Parkinson's disease (IPD)?\n\nYes, the patient has been diagnosed with Parkinson's disease, which meets the inclusion criterion.\n\n#2. Does the patient have any of the exclusion criteria?\n\nNo, the patient does not have any of the exclusion criteria (Parkinson plus syndromes, drug-induced parkinsonism, inability to walk independently or wheelchair-bound, or inability to provide informed consent).\n\nTherefore, based on the information provided, the patient would be eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9959105853},{"ID":"17358_36-2021_NCT04136093","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have central obesity?\n\nYes, the patient has central obesity, as indicated by her waist circumference (WC) of 113 cm, which is greater than or equal to 80 cm. Therefore, the patient meets the inclusion criterion for central obesity.\n\n#2: Is the patient postmenopausal?\n\nYes, the patient is postmenopausal, as indicated by her absence of menses for over 12 months or her serum follicle stimulating hormone (FSH) level of >30 IU\/mL. Therefore, the patient meets the inclusion criterion for postmenopausal status.\n\n#3: Does the patient wish to lose weight and have at least one other criterion of metabolic syndrome?\n\nYes, the patient wishes to lose weight and has at least one other criterion of metabolic syndrome, as indicated by her high blood pressure, high triglycerides, low HDL cholesterol, and high fasting blood glucose. Therefore, the patient meets the inclusion criterion for wishing to lose weight and having at least one other criterion of metabolic syndrome.\n\n#4: Is the patient willing to discontinue any medications that may interfere with the study?\n\nNo information is provided in the patient note about the patient's willingness to discontinue any medications that may interfere with the study. Therefore, this criterion is not met.\n\n#5: Does the patient have any exclusion criteria?\n\nNo information is provided in the patient note about the patient having any exclusion criteria. Therefore, the patient does not meet any exclusion criteria.\n\nBased on the patient note and the inclusion and exclusion criteria for the clinical trial, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible","PROBA":0.9940337586},{"ID":"16918_36-2021_NCT00489333","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\nPlease select one of the following options:\n\nA: Eligible\nB: Excluded\nC: Irrelevant\n\nPlease provide your answer.","PROBA":0.9964904862},{"ID":"24954_53-2021_NCT00377312","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\nThe patient is a healthy Caucasian, Hispanic, or Asian subject, which meets the inclusion criteria.\n\n#2: Does the patient meet the exclusion criteria?\n\nThe patient does not have any of the exclusion criteria, such as cardiac, hypertensive, vascular, renal, pulmonary, endocrine, musculoskeletal, hepatic, hematologic, or malignant disease, anemia, significant alcohol or drug abuse, baseline hypotension, or abnormal levels of any of the screening labs. Additionally, the patient is not pregnant and has not received any investigational drug in the past 90 days.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9899941258},{"ID":"5483_12-2021_NCT03768115","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have dry eye symptoms that cannot be managed with currently available dry eye medication?\n\nYes, the patient has dry eye symptoms that cannot be managed with currently available dry eye medication. Therefore, the patient meets the first inclusion criterion.\n\n#2. Does the patient have a TBUT of \u226410 seconds?\n\nYes, the patient has a TBUT of \u226410 seconds. Therefore, the patient meets the second inclusion criterion.\n\n#3. Does the patient have corneal fluorescein staining?\n\nYes, the patient has corneal fluorescein staining. Therefore, the patient meets the third inclusion criterion.\n\n#4. Is the patient's visual acuity affected by poor tear film quality?\n\nYes, the patient's visual acuity is affected by poor tear film quality. Therefore, the patient meets the fourth inclusion criterion.\n\n#5. Is the patient free of any contraindications for blood extraction\/plasmapheresis?\n\nYes, the patient is free of any contraindications for blood extraction\/plasmapheresis. Therefore, the patient meets the fifth inclusion criterion.\n\n#6. Is the patient between the ages of 21 and 99?\n\nYes, the patient is between the ages of 21 and 99. Therefore, the patient meets the sixth inclusion criterion.\n\n#7. Does the patient have skin lesions at the site of venepuncture in the antecubital area?\n\nNo, the patient does not have skin lesions at the site of venepuncture in the antecubital area. Therefore, the patient meets the seventh inclusion criterion.\n\nBased on the above assessment, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible","PROBA":0.9954356866},{"ID":"35513_75-2021_NCT02086825","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have cirrhosis of the liver?\n\n#2: Does the patient have acute renal failure?\n\n#3: Is the patient's liver function adequate to tolerate lactulose?\n\n#4: Is the patient able to provide informed consent?\n\nPlease answer each question with either \"yes\" or \"no\" before moving on to the next question.","PROBA":0.9582653169},{"ID":"23291_33-2022_NCT01699607","TOPIC_YEAR":2022,"RESPONSE":"#1: Age\n\nThe patient is 20 years old, which is within the age range of 18-55 years for the clinical trial. Therefore, the patient meets the inclusion criterion for age.\n\n#2: Gender\n\nThe patient is male, which is within the inclusion criteria for gender.\n\n#3: Medical condition\n\nThe patient has Marfan syndrome, which is a medical condition that is not an exclusion criterion for the clinical trial.\n\n#4: Substance use\n\nThe patient does not have a history of substance use, which meets the inclusion criterion for this aspect.\n\n#5: Other criteria\n\nThe patient is able to read and write, has given voluntary written informed consent, and has no current uncontrolled medical condition or history of neurological or psychiatric disorder. Therefore, the patient meets all the inclusion criteria for the clinical trial.\n\nBased on the information provided, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible.","PROBA":0.9865260426},{"ID":"7102_15-2021_NCT04852406","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have a history of cardiovascular and cerebrovascular diseases?\n\nYes, the patient has a history of coronary artery disease, atrial fibrillation, and hypertension, which are all cardiovascular and cerebrovascular diseases. Therefore, this criterion is met.\n\n#2. Does the patient have one or more of the following situations?\n\nYes, the patient has a history of non-valvular atrial fibrillation with a CHA2DS2-VASc score >4, which meets one of the inclusion criteria.\n\n#3. Is the patient scheduled to undergo intra-abdominal surgery?\n\nNo, the patient is not scheduled to undergo intra-abdominal surgery. This criterion is not met.\n\n#4. Is the patient willing to sign a written informed consent?\n\nNo information is provided about the patient's willingness to sign a written informed consent. This criterion is not met.\n\nBased on the information provided, the patient is not eligible for the clinical trial because they do not meet criterion #3 (scheduled to undergo intra-abdominal surgery) and criterion #4 (willingness to sign a written informed consent).","PROBA":0.9948828737},{"ID":"35755_75-2021_NCT04207268","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\n#3: Final answer (eligible, excluded, or irrelevant)\n\nPlease provide your answer based on the information provided.","PROBA":0.9788213367},{"ID":"17263_36-2021_NCT03308487","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient meet the inclusion criteria?\n\n#2. Does the patient meet the exclusion criteria?\n\nPlease select one of the following options:\n\nA. Eligible\nB. Excluded\nC. Irrelevant\n\nPlease provide your answer.","PROBA":0.9738027381},{"ID":"35416_75-2021_NCT01161966","TOPIC_YEAR":2021,"RESPONSE":"#1. Is the patient a healthy, normal adult man or non-child bearing potential woman who volunteers to participate?\n\nYes, the patient is a healthy, normal adult man who volunteers to participate. Therefore, the patient meets the inclusion criterion.\n\n#2. Is the patient at least 18 years of age?\n\nYes, the patient is at least 18 years of age. Therefore, the patient meets the inclusion criterion.\n\n#3. Is his\/her BMI between 19 and 30, inclusive?\n\nNo, the patient's BMI is not between 19 and 30. Therefore, the patient does not meet the inclusion criterion.\n\n#4. Is s\/he considered reliable and capable of understanding his\/her responsibility and role in the study?\n\nYes, the patient is considered reliable and capable of understanding his\/her responsibility and role in the study. Therefore, the patient meets the inclusion criterion.\n\n#5. Has s\/he provided written informed consent?\n\nYes, the patient has provided written informed consent. Therefore, the patient meets the inclusion criterion.\n\n#6. Does the patient have a history of allergy or hypersensitivity to zonisamide or sulfonamides?\n\nNo, the patient does not have a history of allergy or hypersensitivity to zonisamide or sulfonamides. Therefore, the patient meets the exclusion criterion.\n\n#7. Does the patient have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his\/her safety?\n\nNo, the patient does not have clinically significant laboratory abnormalities. Therefore, the patient meets the inclusion criterion.\n\n#8. Does the patient have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his\/her safety?\n\nNo, the patient does not have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases. Therefore, the patient meets the inclusion criterion.\n\n#9. Does the patient have serious psychological illness?\n\nNo, the patient does not have serious psychological illness. Therefore, the patient meets the inclusion criterion.\n\n#10. Does the patient have significant history (within the past year) or clinical evidence of alcohol or drug abuse?\n\nNo, the patient does not have significant history (within the past year) or clinical evidence of alcohol or drug abuse. Therefore, the patient meets the inclusion criterion.\n\n#11. Does the patient have a positive urine drug screen, or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test?\n\nNo, the patient does not have a positive urine drug screen, or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test. Therefore, the patient meets the inclusion criterion.\n\n#12. Has the patient consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation?\n\nNo, the patient has not consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation. Therefore, the patient meets the inclusion criterion.\n\n#13. Is the patient unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken?\n\nNo, the patient is not unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken. Therefore, the patient meets the inclusion criterion.\n\n#14. Has the patient used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?\n\nNo, the patient has not used any prescription drug during the 14-","PROBA":0.9993207933},{"ID":"14273_30-2021_NCT04482907","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have multi-nodular goiter?\n\nYes, the patient has multi-nodular goiter.\n\n#2. Is the patient euthyroid?\n\nYes, the patient is euthyroid.\n\n#3. Is the patient over the age of 18?\n\nYes, the patient is over the age of 18.\n\n#4. Does the patient accept the research?\n\nYes, the patient accepts the research.\n\nTherefore, based on the inclusion criteria, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9831578105},{"ID":"6772_15-2021_NCT01945125","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have normal renal function?\n\nBased on the patient's recent lab results, her serum creatinine (SCr) level is 2.1 mg\/dL in [**3-17**], which is within the normal range for her age and gender. Additionally, her estimated glomerular filtration rate (eGFR) is calculated to be 68 mL\/min\/1.73m2, which is also within the normal range. Therefore, the patient meets the inclusion criterion of normal renal function.\n\n#2. Does the patient have any history of renal metastasis?\n\nThere is no mention of renal metastasis in the patient's history. Therefore, the patient does not meet the exclusion criterion of renal metastasis.\n\nBased on the patient's history and recent lab results, she is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9932359281},{"ID":"11756_17-2022_NCT02627339","TOPIC_YEAR":2022,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\nPlease select one of the options in the bracket at the end of each question to indicate your answer.\n\nLet's begin!\n\nQuestion #1: Does the patient meet the inclusion criteria?\n\nThe patient is 67 years old and has slowly worsening vision in both eyes. This suggests that the patient does not have any eye diseases, which is an inclusion criterion. Therefore, the answer is [A: eligible].\n\nQuestion #2: Does the patient meet the exclusion criteria?\n\nThe patient does not have any of the exclusion criteria listed, such as glaucoma, macular degeneration, diabetic retinopathy, corneal disease, eye movement disorders, or any eye disease causing vision loss. Additionally, the patient's visual acuity is not worse than 20\/40, and they do not have cataracts or opacities 2+ or greater. Therefore, the answer is [B: excluded].\n\nBased on the answers to the questions, the patient is not eligible for the clinical trial.","PROBA":0.9906014021},{"ID":"27553_40-2022_NCT00835211","TOPIC_YEAR":2022,"RESPONSE":"The patient is a 23-year-old female who has prolonged oral bleeding after a tooth extraction. She has a history of heavy menstrual cycles and a family history of excessive bleeding during menstrual periods. She does not have any other medical conditions and is not taking any medications.\n\nBased on the inclusion criteria of the clinical trial, the patient is eligible for the study. The trial is looking for healthy adult non-smokers or light smokers between the ages of 18 and 55, and the patient meets these criteria. Additionally, the patient does not have any exclusion criteria, such as pregnancy or a history of bleeding disorders, that would disqualify her from participating in the study.\n\nTherefore, the patient is eligible for the clinical trial.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n","PROBA":0.9973405689},{"ID":"35758_75-2021_NCT04222088","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\n\nThe patient is 55 years old, which is within the age range of 6 months to 59 years old required for the clinical trial. Therefore, the patient meets the inclusion criterion for age.\n\n#2: Type of malaria\n\nThe patient has P. falciparum malaria, which is one of the types of malaria included in the clinical trial. Therefore, the patient meets the inclusion criterion for type of malaria.\n\n#3: Parasitemia level\n\nThe patient has a parasitemia level of 1000-100,000 asexual forms per \u00b5l, which is within the range of 1000-100,000 asexual forms per \u00b5l required for the clinical trial. Therefore, the patient meets the inclusion criterion for parasitemia level.\n\n#4: Temperature\n\nThe patient has an axillary temperature of 38\u00b0C, which is within the range of 37.5\u00b0C to 38\u00b0C required for the clinical trial. Therefore, the patient meets the inclusion criterion for temperature.\n\n#5: Ability to swallow medication\n\nThe patient is able to swallow medication, which is a requirement for the clinical trial. Therefore, the patient meets the inclusion criterion for ability to swallow medication.\n\n#6: Ability and willingness to comply with the study protocol\n\nThe patient is able and willing to comply with the study protocol for the duration of the study, which is a requirement for the clinical trial. Therefore, the patient meets the inclusion criterion for ability and willingness to comply with the study protocol.\n\n#7: Informed consent\n\nThe patient has provided informed consent for participation in the clinical trial. Therefore, the patient meets the inclusion criterion for informed consent.\n\nSince the patient meets all the inclusion criteria and none of the exclusion criteria, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible.","PROBA":0.9918591678},{"ID":"30870_65-2021_NCT03605979","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the age criteria?\n\n#2: Does the patient have type 1 diabetes?\n\n#3: Has the patient been treated with insulin pump for more than three months?\n\n#4: Does the patient have hypoglycemia unawareness?\n\n#5: Does the patient meet any of the exclusion criteria?\n\nPlease answer each question with either \"yes\" or \"no\" before moving on to the next question.","PROBA":0.9708251986},{"ID":"35323_75-2021_NCT00282152","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a clinical diagnosis of probable idiopathic Parkinson's disease?\n\nYes, the patient has a clinical diagnosis of probable idiopathic Parkinson's disease.\n\n#2: Does the patient have a demonstrated response to dopaminergic therapy?\n\nYes, the patient has demonstrated a response to dopaminergic therapy, with at least 30% improvement in parkinsonian motor signs based on the UPDRS motor examination subscore.\n\n#3: Is the patient at Hoehn and Yahr stage II when OFF medication?\n\nYes, the patient is at Hoehn and Yahr stage II when OFF medication.\n\n#4: Are there any contraindications to surgery?\n\nNo, there are no contraindications to surgery.\n\n#5: Is the patient within the age range of 50-75 years old?\n\nYes, the patient is within the age range of 50-75 years old.\n\n#6: Is the patient available for follow-up for four years?\n\nYes, the patient is available for follow-up for four years.\n\n#7: Does the patient have an informed consent?\n\nYes, the patient has an informed consent.\n\n#8: Does the patient have MRI within normal range for age?\n\nYes, the patient has MRI within normal range for age.\n\n#9: Has the patient been on levodopa or dopamine agonist therapy for greater than six months but less than or equal to four years?\n\nYes, the patient has been on levodopa or dopamine agonist therapy for greater than six months but less than or equal to four years.\n\nBased on the above answers, the patient is eligible for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial. The answer is A: eligible.","PROBA":0.9956128979}]
